Although advances in biological medicine have seen significant progress in the treatment of
autoimmune and inflammatory disease, many patients do not experience a satisfactory
response. Hence, there are two challenges facing the medical research community. The first
is to continue development in the field of existing biological therapies, such as monoclonal
antibodies. The second is to open new frontiers of research and explore treatment
alternatives for non-responders to other therapies. Attention has increasingly turned to the …